Skip to main content
Premium Trial:

Request an Annual Quote

Informax Releases Genomax 3.0

NEW YORK, Sept 18 – Bioinformatics company Informax of Rockville, Md., said Monday it had released version 3.0 of Genomax, a software package that includes modules for sequence analysis, gene expression analysis, and 3-dimensional protein structure.

The software, which is geared to help pharmaceutical and biotechnology companies to integrate vast amounts of data, is designed for a multi-user environment. The software employs Oracle relational databases as well as a Java-based graphical user interface.

Genomax users include DuPont, Genzyme, Pioneer Hi-Bred, the University of Tokyo, and Massachusetts Institute of Technology.

The company said it is currently working on integrating new modules into Genomax, including genomic viewing, protein-protein interaction, and SNP analysis.

Informax’s other main product is Vector NTI, a desktop application used for sequence analysis and visualization.

The company reported revenues of $3.2 million in first-quarter 2000, up from $1.6 million in the year ago period. Software sales accounted for $2.4 million of this year’s first-quarter sales.

The company is planning to raise $75 million in an initial public offering on the Nasdaq within the next month.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.